Clearside Biomedical Inc., of Alpharetta, Ga., is closing a $20 million series C financing that will help it further advance development of its suprachoroidal space microinjector to administer drugs to the posterior segment of the eye for the treatment of diseases such as uveitis, retinal vein occlusion and wet age-related macular degeneration. The financing included new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management, along with existing Clearside investors.

Prosetta Biosciences Inc., of San Francisco, raised about $31 million in gross proceeds in a private placement. Net proceeds will be used primarily for R&D, with an emphasis in the fields of central nervous system diseases and disorders, oncology, inflammation, anti-infectives, vaccines, animal health and biodefense, among other fields, and for working capital and general corporate purposes. Investors in the series D private placement included Alger Management and Osaka, Japan-based Takeda Pharmaceutical Co. Ltd.